Upgrade to SI Premium - Free Trial

Ocugen (OCGN)

1.19 -0.05 (4.03%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/31/26)

Latest Headlines

Form 8-K Ocugen, Inc. For: May 29 June 3, 2026 4:32 PM - SEC Filing Ocugen to Participate in Upcoming June Investor and Industry Conferences June 2, 2026 7:03 AM - StreetInsider Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord May 26, 2026 1:18 PM - StreetInsider Ocugen appoints new acting chief medical officer May 14, 2026 4:41 PM - StreetInsider Form 8-K Ocugen, Inc. For: May 08 May 14, 2026 4:32 PM - SEC Filing Form 8-K Ocugen, Inc. For: May 14 May 14, 2026 4:31 PM - SEC Filing Ocugen raises $130 million through convertible notes offering May 14, 2026 4:30 PM - StreetInsider Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes May 14, 2026 4:30 PM - StreetInsider Ocugen to Participate in Upcoming May Scientific and Investor Conferences May 13, 2026 7:02 AM - Globe NewsWire Form 10-Q Ocugen, Inc. For: Mar 31 May 8, 2026 6:05 AM - SEC Filing Form 8-K Ocugen, Inc. For: May 07 May 7, 2026 4:15 PM - SEC Filing Form 8-K Ocugen, Inc. For: May 05 May 5, 2026 11:37 AM - SEC Filing Ocugen (OCGN) Misses Q1 EPS by 1c May 5, 2026 8:42 AM - StreetInsider Ocugen completes $115 million convertible notes offering to extend runway May 5, 2026 8:34 AM - StreetInsider Ocugen Provides Business Update with First Quarter 2026 Financial Results May 5, 2026 8:32 AM - Globe NewsWire Ocugen prices $115 million convertible notes at 6.75% interest May 5, 2026 8:12 AM - StreetInsider Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes May 5, 2026 8:12 AM - Globe NewsWire Form 8-K Ocugen, Inc. For: May 04 May 4, 2026 4:04 PM - SEC Filing Ocugen announces $115 million convertible notes offering May 4, 2026 4:02 PM - StreetInsider Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes May 4, 2026 4:01 PM - Globe NewsWire Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results April 29, 2026 7:02 AM - Globe NewsWire Form DEFA14A Ocugen, Inc. April 28, 2026 7:02 AM - SEC Filing Form ARS Ocugen, Inc. For: Dec 31 April 28, 2026 7:01 AM - SEC Filing Form DEF 14A Ocugen, Inc. For: Jun 11 April 28, 2026 7:01 AM - SEC Filing Ocugen to Present at April 2026 Investor and Industry Conferences April 23, 2026 7:02 AM - StreetInsider Form PRER14A Ocugen, Inc. April 20, 2026 5:19 PM - SEC Filing Form PRE 14A Ocugen, Inc. For: Jun 11 April 17, 2026 4:57 PM - SEC Filing Form SCHEDULE 13G Ocugen, Inc. Filed by: MILLENNIUM MANAGEMENT LLC April 14, 2026 6:38 PM - SEC Filing Form 4 Ocugen, Inc. For: Apr 01 Filed by: Zhang Junge April 2, 2026 9:27 PM - SEC Filing Ocugen completes dosing in phase 2/3 trial for Stargardt disease therapy April 1, 2026 7:02 AM - StreetInsider Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease April 1, 2026 7:02 AM - StreetInsider Form SCHEDULE 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 11:06 AM - SEC Filing Form 8-K Ocugen, Inc. For: Mar 26 March 27, 2026 6:04 AM - SEC Filing Ocugen, Inc. (OCGN) PT Raised to $12 at Noble Capital March 25, 2026 9:22 AM - StreetInsider Ocugen, Inc. (OCGN) PT Raised to $10 at H.C. Wainwright March 25, 2026 6:54 AM - StreetInsider Form 8-K Ocugen, Inc. For: Mar 24 March 24, 2026 12:03 PM - SEC Filing Ocugen reports 31% lesion reduction in gene therapy trial March 24, 2026 7:45 AM - StreetInsider Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration March 24, 2026 7:45 AM - StreetInsider Ocugen to host webcast on phase 2 trial data for geographic atrophy therapy March 23, 2026 7:02 AM - StreetInsider Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy March 23, 2026 7:02 AM - StreetInsider Form 8-K Ocugen, Inc. For: Mar 12 March 20, 2026 8:00 AM - SEC Filing Canaccord Starts Ocugen, Inc. (OCGN) at Buy March 17, 2026 7:27 AM - StreetInsider Full Article List